335 related articles for article (PubMed ID: 25212872)
1. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.
Surolia I; Gulley J; Madan RA
Expert Opin Biol Ther; 2014 Dec; 14(12):1769-81. PubMed ID: 25212872
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in genitourinary malignancies.
Wattenberg MM; Fong L; Madan RA; Gulley JL
Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
[TBL] [Abstract][Full Text] [Related]
3. Novel immunotherapies in GU malignancies.
Drakaki A; McDermott DF
Curr Oncol Rep; 2013 Jun; 15(3):224-31. PubMed ID: 23519772
[TBL] [Abstract][Full Text] [Related]
4. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
5. Novel immunotherapy combinations for genitourinary cancers.
Al Harthy M; Redman J; Madan RA
Expert Opin Biol Ther; 2020 Mar; 20(3):253-262. PubMed ID: 31914333
[TBL] [Abstract][Full Text] [Related]
6. Combination immunotherapy in genitourinary malignancies.
Hoffman-Censits J; Wilde L
Curr Opin Urol; 2016 Nov; 26(6):523-8. PubMed ID: 27517637
[TBL] [Abstract][Full Text] [Related]
7. Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
Alme AK; Karir BS; Faltas BM; Drake CG
Urol Oncol; 2016 Apr; 34(4):171-81. PubMed ID: 26923782
[TBL] [Abstract][Full Text] [Related]
8. Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis.
Maisch P; Koll F; Bolenz C; Chun FK; Gschwend JE; Schmid SC
Urol Oncol; 2023 May; 41(5):219-232. PubMed ID: 36372634
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for genitourinary tumors.
Nakayama T; Kitano S
Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
[TBL] [Abstract][Full Text] [Related]
10. An Overview of Emerging Immunotargets of Genitourinary Tumors.
Montironi R; Santoni M; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Scarpelli M
Curr Drug Targets; 2016; 17(7):750-6. PubMed ID: 26648079
[TBL] [Abstract][Full Text] [Related]
11. Current Landscape of Immunotherapy in Genitourinary Malignancies.
Alhalabi O; Rafei H; Bilen MA; Shah AY
Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
[TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
Bigot F; Bonnet C; Massard C
Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
[TBL] [Abstract][Full Text] [Related]
13. [Combination radiotherapy-immunotherapy in genitourinary cancer].
Ollivier L; Guimas V; Rio E; Vaugier L; Masson I; Libois V; Labbé M; Fradin D; Potiron V; Supiot S
Cancer Radiother; 2021 Oct; 25(6-7):565-569. PubMed ID: 34391648
[TBL] [Abstract][Full Text] [Related]
14. Landscape of Immunotherapy in Genitourinary Malignancies.
Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
[TBL] [Abstract][Full Text] [Related]
15. Role of immunotherapy in the treatment of bladder and renal cell carcinoma.
Stone NN; Droller MJ
Semin Surg Oncol; 1991; 7(4):239-43. PubMed ID: 1925256
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo gene therapy using granulocyte-macrophage colony-stimulating factor-transduced tumor vaccines.
Kawai K; Tani K; Asano S; Akaza H
Mol Urol; 2000; 4(2):43-6. PubMed ID: 12006240
[TBL] [Abstract][Full Text] [Related]
17. The role of immunotherapy for urological tumours.
Hrouda D; Muir GH; Dalgleish AG
Br J Urol; 1997 Mar; 79(3):307-16. PubMed ID: 9117206
[No Abstract] [Full Text] [Related]
18. [The studies of natural killer cell activity in uro-genital cancer patients--investigation of natural killer cell activity from the standpoint of stage and antitumor therapy of genito-urinary tract carcinomas].
Fukasawa K
Nihon Hinyokika Gakkai Zasshi; 1988 Feb; 79(2):239-45. PubMed ID: 3226000
[No Abstract] [Full Text] [Related]
19. Recent progress in immunotherapy for urological cancer.
Obara W; Kato R; Kato Y; Kanehira M; Takata R
Int J Urol; 2017 Oct; 24(10):735-742. PubMed ID: 28636222
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for urological malignancies.
Krejci KG; Markiewicz MA; Kwon ED
J Urol; 2004 Feb; 171(2 Pt 1):870-6. PubMed ID: 14713844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
